

# Brian C-H Chiu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1906704/publications.pdf>

Version: 2024-02-01

63  
papers

2,259  
citations

279487

23  
h-index

214527

47  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. <i>Blood</i> , 2008, 111, 4029-4038.	0.6	508
2	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010, 116, e90-e98.	0.6	200
3	Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 2195-2205.	6.1	180
4	An Update of the Epidemiology of Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 161-168.	2.1	152
5	Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2008, 122, 2062-2070.	2.3	104
6	Diet and Risk of Non-Hodgkin Lymphoma in Older Women. <i>JAMA - Journal of the American Medical Association</i> , 1996, 275, 1315.	3.8	102
7	Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 1363-1369.	0.6	91
8	Epidemiology and Etiology of Non-Hodgkin Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 1-25.	0.2	88
9	Body Mass Index, Abnormal Glucose Metabolism, and Mortality from Hematopoietic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2348-2354.	1.1	70
10	Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study. <i>British Journal of Haematology</i> , 2005, 128, 610-615.	1.2	61
11	Dietary factors and risk of colon cancer in Shanghai, China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 201-8.	1.1	54
12	Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. <i>Cancer Communications</i> , 2019, 39, 1-9.	3.7	53
13	Alcohol Consumption, Family History of Hematolymphoproliferative Cancer, and the Risk of Non-Hodgkin's Lymphoma in Men. <i>Annals of Epidemiology</i> , 2002, 12, 309-315.	0.9	42
14	Tumor necrosis factor- $\alpha$ inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	2.3	42
15	Obesity and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , 2007, 18, 677-685.	0.8	37
16	Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2790-2799.	2.5	36
17	Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. <i>Blood Cancer Journal</i> , 2020, 10, 80.	2.8	35
18	Pesticides, Chromosomal Aberrations, and Non-Hodgkin's Lymphoma. <i>Journal of Agromedicine</i> , 2009, 14, 250-255.	0.9	32

#	ARTICLE	IF	CITATIONS
19	An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. <i>Leukemia and Lymphoma</i> , 2013, 54, 1677-1683.	0.6	32
20	Cigarette Smoking, Familial Hematopoietic Cancer, Hair Dye Use, and Risk of t(14;18)-defined Subtypes of Non-Hodgkin's Lymphoma. <i>American Journal of Epidemiology</i> , 2007, 165, 652-659.	1.6	26
21	Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2011, 22, 1183-1195.	0.8	25
22	Phytanic acid and the risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2013, 34, 170-175.	1.3	25
23	Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2008, 19, 859-867.	0.8	24
24	Meat intake and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2012, 23, 1681-1692.	0.8	23
25	Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 525-31.	1.1	21
26	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	2.5	16
27	Application of the High-Throughput TAB-Array for the Discovery of Novel 5-Hydroxymethylcytosine Biomarkers in Pancreatic Ductal Adenocarcinoma. <i>Epigenomes</i> , 2019, 3, 16.	0.8	15
28	The Challenges of Epidemiologic Research in Non-Hodgkin Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2059.	3.8	14
29	Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. <i>Cancer</i> , 2019, 125, 1143-1154.	2.0	14
30	The Utility of t(14;18) in Understanding Risk Factors for Non-Hodgkin Lymphoma. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 69-73.	0.9	13
31	Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma. <i>Npj Genomic Medicine</i> , 2021, 6, 11.	1.7	13
32	Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2020, 28, 4097-4106.	1.0	12
33	Sex differences in outcomes in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 192, e66-e69.	1.2	12
34	Dietary nitrate and nitrite intake and risk of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 945-950.	0.6	10
35	Associations between frailty and cancer-specific mortality among older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 769-779.	1.1	10
36	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Self-reported health and survival in older patients diagnosed with multiple myeloma. <i>Cancer Causes and Control</i> , 2020, 31, 641-650.	0.8	7
38	Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare. <i>JCO Oncology Practice</i> , 2021, 17, e294-e312.	1.4	7
39	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. <i>International Journal of Cancer</i> , 2020, 147, 1300-1305.	2.3	6
40	Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 7-12.	1.1	5
41	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. <i>Cancer Causes and Control</i> , 2019, 30, 889-900.	0.8	4
42	Treatment of older patients with diffuse large B-cell lymphoma and mild cognitive impairment or dementia. <i>Journal of Geriatric Oncology</i> , 2019, 10, 510-513.	0.5	4
43	Long Term Statin Use and Risk of Multiple Myeloma Among 15.5 Million Taiwanese Adults: A Retrospective Cohort Study. <i>Blood</i> , 2015, 126, 4198-4198.	0.6	4
44	The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. <i>Breast Cancer</i> , 2022, 29, 287-295.	1.3	4
45	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 23664.	1.6	4
46	Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. <i>Medicine (United States)</i> , 2019, 98, e17960.	0.4	3
47	TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases. <i>Blood</i> , 2018, 132, 2984-2984.	0.6	3
48	Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma. <i>Blood</i> , 2021, 138, 4116-4116.	0.6	3
49	Loss of 5-hydroxymethylcytosine expression is nearuniversal in B-cell lymphomas with variable mutations in epigenetic regulators. <i>Haematologica</i> , 2021, , .	1.7	2
50	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e2118410.	2.8	1
51	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). <i>Blood</i> , 2016, 128, 3250-3250.	0.6	1
52	Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma. <i>Blood</i> , 2015, 126, 2954-2954.	0.6	1
53	Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors. <i>Blood</i> , 2015, 126, 2653-2653.	0.6	0
54	Race and Socioeconomic Factors Influencing Treatment Disparities and Comparative Effectiveness in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 841-841.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Racial Differences in Long-Term Risk of Venous Thromboembolism Among Older Patients Following Diagnosis and Treatment of Multiple Myeloma. Blood, 2016, 128, 2071-2071.	0.6	0
56	5-Hydroxymethylcytosines of Circulating Cell-Free DNA and Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 2985-2985.	0.6	0
57	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. Blood, 2018, 132, 4693-4693.	0.6	0
58	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. Blood, 2018, 132, 1888-1888.	0.6	0
59	Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma. Blood, 2019, 134, 5494-5494.	0.6	0
60	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. Blood, 2019, 134, 4379-4379.	0.6	0
61	Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 3789-3789.	0.6	0
62	Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race. Blood, 2020, 136, 40-41.	0.6	0
63	Physical functioning, frailty and risks of locally-advanced breast cancer among older women. Breast, 2022, 64, 19-28.	0.9	0